Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
BIOMARKER:
Chr del(17p)
Associations
(75)
Heatmap
News
Twitter
Trials
A1 | Sensitive
A2 | Sensitive
B | Sensitive
C2 | Sensitive
C3 | Sensitive
D | Sensitive
A1 | Resistant
A2 | Resistant
B | Resistant
C2 | Resistant
C3 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
BCL Inhibitors
CD Protein Inhibitors
Immunotherapy
Tyrosine Kinase Inhibitors
PI3 Kinase Inhibitors
Immune Checkpoint Inhibitors
Proteasome Inhibitors
Interleukins
Chemotherapy
DNA
Epigenetics
Kinase Inhibitors
Cancel
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Multiple Myeloma
Acute Myelogenous Leukemia
Non-Hodgkin’s Lymphoma
Myelodysplastic Syndrome
lenalidomide
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
lenalidomide
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
lenalidomide
obinutuzumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab
B
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
obinutuzumab
pembrolizumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
pembrolizumab
rituximab + alemtuzumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
rituximab + alemtuzumab
obinutuzumab + acalabrutinib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
obinutuzumab + acalabrutinib
duvelisib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
duvelisib
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
duvelisib
ofatumumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ofatumumab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
ofatumumab
rituximab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
rituximab
venetoclax + rituximab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + rituximab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
venetoclax + rituximab
zanubrutinib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
zanubrutinib
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
zanubrutinib
alemtuzumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
alemtuzumab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
alemtuzumab
rituximab + lenalidomide
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
rituximab + lenalidomide
idelalisib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
idelalisib
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
idelalisib
pembrolizumab + ibrutinib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib
nivolumab
A2
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
nivolumab
DVD
B
Chr del(17p)
|
Multiple Myeloma
|
DVD
Isa-KRd
C2
Chr del(17p)
|
Multiple Myeloma
|
Isa-KRd
T-lymphocyte cell therapy
C3
Chr del(17p)
|
Non-Hodgkin’s Lymphoma
|
T-lymphocyte cell therapy
FCR
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
FCR
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
FCR
Proteasome inhibitor + Immunomodulator
C3
Chr del(17p)
|
Multiple Myeloma
|
Proteasome inhibitor + Immunomodulator
BTK inhibitor
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
BTK inhibitor
daratumumab
B
Chr del(17p)
|
Multiple Myeloma
|
daratumumab
ibrutinib + ublituximab
B
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
ibrutinib + ublituximab
bortezomib + selinexor
B
Chr del(17p)
|
Multiple Myeloma
|
bortezomib + selinexor
lenalidomide + isatuximab-irfc
B
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc
lenalidomide + elotuzumab
B
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + elotuzumab
acalabrutinib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
acalabrutinib
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
acalabrutinib
rituximab + idelalisib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
rituximab + idelalisib
venetoclax
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
venetoclax
ibrutinib
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ibrutinib
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
ibrutinib
venetoclax + obinutuzumab
A2
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
venetoclax + obinutuzumab
LOXO-305
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
LOXO-305
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
LOXO-305
orelabrutinib
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
orelabrutinib
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
orelabrutinib
venetoclax + ibrutinib
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
venetoclax + ibrutinib
obinutuzumab + zanubrutinib
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
obinutuzumab + zanubrutinib
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
obinutuzumab + zanubrutinib
ibrutinib + lisocabtagene maraleucel
C3
Chr del(17p)
|
Small Lymphocytic Lymphoma
|
ibrutinib + lisocabtagene maraleucel
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
ibrutinib + lisocabtagene maraleucel
bortezomib
C3
Chr del(17p)
|
Multiple Myeloma
|
bortezomib
lenalidomide + tafasitamab
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
lenalidomide + tafasitamab
idelalisib + ofatumumab
A1
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
idelalisib + ofatumumab
RP6530
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
RP6530
ibrutinib + UC-961
C3
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
ibrutinib + UC-961
selinexor
C3
Chr del(17p)
|
Multiple Myeloma
|
selinexor
MGD006
C3
Chr del(17p)
|
Acute Myelogenous Leukemia
|
MGD006
melphalan flufenamide
C3
Chr del(17p)
|
Multiple Myeloma
|
melphalan flufenamide
lenalidomide + ixazomib
C3
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + ixazomib
azacitidine
C3
Chr del(17p)
|
Myelodysplastic Syndrome
|
azacitidine
thalidomide
C3
Chr del(17p)
|
Multiple Myeloma
|
thalidomide
MRT68921
D
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
MRT68921
Compound C
D
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
Compound C
hydroxychloroquine
D
Chr del(17p)
|
Chronic Lymphocytic Leukemia
|
hydroxychloroquine
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
